Regeneron will provide Otarmeni at no cost to U.S. patients affected by a specific genetic form of hearing loss, targeting a small pediatric population with the newly approved gene therapy. CEO Leonard Schleifer emphasized the company’s commitment to patient access while leveraging its manufacturing capabilities.

Pricing for Otarmeni in international markets remains under review, with Regeneron yet to establish dollar figures or reimbursement pathways outside the U.S., creating potential variability in future revenue streams. The decision will influence market entry strategy and global sales forecasts.

Regeneron shares dropped roughly 3% after the company joined the White House’s Trump Rx drug-pricing platform, signaling intensified government scrutiny over drug costs. Investors are assessing how this aligns with Regeneron’s pricing flexibility and long-term profit margins.